

Special Issue

Early Diagnosis Research of Inherited Neuropathies

Message from the Guest Editors

The diagnosis of inherited neuropathies has been largely improved in the last decade. However, numerous patients are still undiagnosed, inducing a lack of adapted clinical care without therapeutic hopes. While single-nucleotide variants and small indel mutations are now easily detected, structural variations, for instance, are still often underdiagnosed. In this issue, we would like to report new technologies, but also new bioinformatics tools developed recently and verified experimentally, to improve the diagnosis of inherited neuropathies. Structural variations, which are new kinds of mutations currently described to be responsible for neuropathies, could be an interesting aspect of this issue. Articles presenting new strategies supported by experimental results or preclinical applications will be considered. This Special Issue will help the diagnosis of neuropathic patients to be improved, and we believe it could serve as a reference for all inherited diseases.

Guest Editors

Prof. Dr. Frédéric Favreau

1. University of Limoges, Faculté de Médecine, EA6309, Limoges, France
2. Service de Biochimie et Génétique Moléculaire, Limoges Hospital, Limoges, France

Dr. Anne-Sophie Lia

1. University of Limoges, Faculté de Médecine, EA6309 Limoges, France
2. Service de Biochimie et Génétique Moléculaire, Limoges Hospital, Limoges, France

Deadline for manuscript submissions

closed (16 November 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/110362

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).